PIOGLITAZONE REDUCES OXIDATIVE STRESS AND DECREASES ATHEROGENIC MARKERS IN MICE WITH METABOLIC SYNDROME

CANNIZZO B; CEJAS J; CAYADO GUTIERREZ N; ABUD M; REDONDO A; CRUZADO M; CASTRO, C

San Luis

Congreso; Reunión Anual de la Sociedad de Biología de Cuyo; 2012

Sociedad de Biología de Cuyo

The metabolic syndrome (MS) increases the risk of type 2 diabetes (T2DM) and cardiovascular diseases. Pioglitazone (PIO) is used to improve insulin sensitivity in patients with T2DM. We analyzed the effect of PIO on the oxidative stress, the expression of inflammatory and endothelial dysfunction markers and the development of atheroma plaque in apolipoprotein E-deficient mice (ApoE-KO). Mice were fed with fructose overload (FF, 10% w / v) for 8 weeks and treated with PIO the latest 4 weeks. Serum level of the lipid peroxidation product, malondialdehyde (MDA) was performed. Atheroma plaques in aortas were measured with Oil Red stain and aortic VCAM-1 and MMP9 expression were determined by western blot. PIO significantly inhibited FF-increased glycaemia, triglyceridemia, insulinemia and MDA levels. No changes in the development of the atheroma plaque stimulated with FF were found, but the expression of VCAM-1 and MMP-9 were significantly diminished by PIO. Our results show that PIO improves insulin sensitivity, diminishes oxidative damage and reduces the expression of pro-atherogenic proteins. These findings suggest that PIO could increase the stability of advanced atherosclerotic plaques in ApoE-KO mice with MS